Erectile Dysfunction Drugs Market Outlook 2031
The global erectile dysfunction drugs market size was valued at USD 2.50 Billion in 2022 and is projected to reach USD 5.21 Billion by 2031, expanding at a CAGR of 8.5% during the forecast period, 2023–2031. The growth of the market is attributed to the rising patients’ awareness about the disorder and growing base of the geriatric population globally.
Erectile dysfunction, also known as impotent, refers to a health disorder that causes constant inability to succor an erection enough for sexual intercourse. Clinically, erectile dysfunction can be understood as a separate issue that is different from other issues that interfere with sexual intercourse.
The shortage of crucial medical needs and the rapid rise in the number of cases of the COVID-19 cases have shifted in the progress of health facilities. The supply chain disruption and travel restrictions have created negative outlook of various major market players especially due to drug shortage worldwide.
Lockdown and government restrictions have negatively impacted the import and export of drugs across the globe owing to the shortage of medicines with many people being denied access to drugs.
The dysfunction is one of the most commonly occurred health condition especially among men and its prevalence widely increases when an individual is becoming older. Older men and aging population have comorbidities such as chronic obstructive pulmonary disease, diabetes mellitus, cardiovascular diseases, and hypertension.
In addition, they simultaneously prefer a medical practitioner for impairments in sexual function mostly for erectile dysfunction. The increase in the number of erectile dysfunction cases is frequently linked with the diabetes, high growth of obesity, and cardiovascular disorders.
Erectile Dysfunction Drugs Market Trends, Drivers, Restraints, and Opportunities
- Rising acceptance of a sedentary lifestyle and increasing prevalence of lifestyle diseases are further anticipated to boost the market growth in the coming years.
- Government and public awareness initiatives to control and diagnose of the disorder is expected to drive market growth during the forecast period.
- Economic development, healthcare infrastructure establishment, and several clinical drugs development are key factors estimated to provide potential growth rate of the market.
- Availability of cost-effective drugs and increase rate of adoption by the patients are key factors propelling the erectile dysfunction drugs market growth.
- Adverse reactions from the existing drugs and unmet clinical needs are expected to hamper the market growth.
Scope of Erectile Dysfunction Drugs Market Report
The report on the global erectile dysfunction drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Erectile Dysfunction Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Products (Viagra, Levitra/Staxyn, Stendra/Spedra, Zydena, and Vitaros)
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Bayer AG; Produtos Quimicos Farmaceuticos Ltd.; Cristalia Dong-A Pharmaceutical Co. Ltd.; Meda Pharmaceuticals, Inc.; Pfizer, Inc.; Eli Lilly and Company; S.K. Chemicals Co. Ltd.; Vivus, Inc.; and Apricus Biosciences Inc.
|
Erectile Dysfunction Drugs Market Segment Insights
Products Segment Analysis
Based on products, the global erectile dysfunction drugs market is segregated into viagra, levitra/staxyn, stendra/spedra, zydena, and vitaros.
The zydena segment is expected to grow at a rapid pace during the forecast period owing to its long duration of action and less incidences of adverse reactions such as vision disturbances and muscle pain. However, the viagra segment is anticipated to expand at a significant growth rate during the forecast period due to increased adoption rate among men.
Regional Outlook
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years owing to presence of a well-established healthcare infrastructure and increased demand for erectile dysfunction drugs in the region.
The market of Asia Pacific, however, is anticipated to expand rapidly during the forecast period due to rising prevalence of erectile dysfunction causing infections, flourishing generic drugs industry, and social stigma in the region.
Segments
The global erectile dysfunction drugs market has been segmented on the basis of
Products
- Viagra
- Levitra/Staxyn
- Stendra/Spedra
- Zydena
- Vitaros
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Bayer AG
- Produtos Quimicos Farmaceuticos Ltd.
- Cristalia Dong-A Pharmaceutical Co. Ltd.
- Meda Pharmaceuticals, Inc.
- Pfizer, Inc.
- Eli Lilly and Company
- S.K. Chemicals Co. Ltd.
- Vivus, Inc.
- Apricus Biosciences Inc.
Competitive Landscape
Key players competing in the global erectile dysfunction drugs market are Bayer AG; Produtos Quimicos Farmaceuticos Ltd.; Cristalia Dong-A Pharmaceutical Co. Ltd.; Meda Pharmaceuticals, Inc.; Pfizer, Inc.; Eli Lilly and Company, S.K. Chemicals Co. Ltd.; Vivus, Inc.; and Apricus Biosciences Inc.
The main market players are continuously engaged in several business development activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market position.